SCHEMBL21608293

SCHEMBL21608293

C=Cc1cnnc(NC(C)=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
PTK2 Q05397 1/20 0.37
PIK3C3 Q8NEB9 2/20 0.36
KDM4E B2RXH2 2/20 0.35
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
ADORA3 P0DMS8 6/20 0.35
GLS O94925 1/20 0.34
CYP1A2 P05177 1/20 0.33
GAA P10253 1/20 0.33
ADORA1 P30542 2/20 0.33
MAP4K4 O95819 1/20 0.33
ABL1 P00519 1/20 0.33
MAPK8 P45983 1/20 0.33
CSNK1A1 P48729 1/20 0.33
CDK7 P50613 1/20 0.33
TYRO3 Q06418 1/20 0.33
LRRK2 Q5S007 1/20 0.33
AURKB Q96GD4 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21607832 0.85 L3MBTL1 (0.43) L3MBTL1PTK2PIK3C3KDM4EHSP90AA1
SCHEMBL22574129 0.77 PTK2 (0.51) L3MBTL1PTK2PIK3C3KDM4EHSP90AA1
SCHEMBL19736366 0.75 PIK3C3 (0.53) L3MBTL1PTK2PIK3C3KDM4EHSP90AA1
SCHEMBL28270171 0.73 L3MBTL1 (0.50) L3MBTL1PIK3C3
SCHEMBL23015784 0.71 L3MBTL1 (0.43) L3MBTL1PTK2PIK3C3KDM4EHSP90AA1
SCHEMBL31006927 0.71 ADORA3 (0.48) L3MBTL1KDM4EADORA3CYP1A2ADORA1
SCHEMBL25298526 0.71 ADORA3 (0.48) L3MBTL1KDM4EADORA3CYP1A2ADORA1
SCHEMBL3660964 0.71 PTK2 (0.57) L3MBTL1PTK2KDM4EHSP90AA1HSP90AB1
SCHEMBL18900235 0.70 L3MBTL1 (0.42) L3MBTL1PTK2PIK3C3KDM4EHSP90AA1
SCHEMBL22207799 0.69 UNG (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210300900-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 US disclosed
WO-2019243531-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300900-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN L3MBTL1 1044/4885PTK2 3463/4885PIK3C3 2525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.